Meeting 11-11-2025
Meeting Topics By Time Block
| Time | Topic |
|---|---|
| 00:01–03:15 | Intro, Announcements & AI Heart Imaging - The host opens the meeting, mentions upcoming AI-powered CT angiography content, and highlights the importance of advanced plaque analysis over traditional calcium scoring. He stresses that clinicians prescribing testosterone must also manage cardiovascular and renal health as part of comprehensive internal medicine care. |
| 03:15–04:20 | Case 1 Introduction (61-year-old male) - Stephanie presents a 61-year-old patient with diabetes, hypertension, dyslipidemia, sleep apnea, obesity, and erectile dysfunction. She outlines his symptoms of fatigue, poor sleep, low libido, reduced muscle mass, and difficulty recovering from exercise. |
| 04:20–06:14 | Review of Symptoms & Lab Findings - Stephanie reviews his lack of chest pain, edema, or psychiatric issues and shares labs showing low vitamin D, elevated A1C, and low free testosterone due to high SHBG. Liver enzymes and electrolytes are normal, and hematocrit is borderline high. |
| 06:14–08:02 | Treatment Plan & Early Management - She explains her initial plan: increase his SGLT2 inhibitor, start vitamin D and aspirin, begin testosterone cypionate 50 mg twice weekly, and consider GLP-1 agonist therapy. She also refers him to cardiology due to severe ED and possible peripheral arterial disease. |
| 08:02–13:01 | Stress Test Results & Discovery of Severe Heart Disease - The cardiologist’s evaluation reveals a positive stress test and significant multivessel coronary artery disease requiring CABG. The host emphasizes that this should have been detected years earlier and credits Stephanie for identifying ED as a cardiovascular warning sign. |
| 13:01–20:32 | Evidence-Based Cardiovascular Management Discussion - The host explains the TRAVERSE Trial, showing testosterone is not associated with increased cardiac events when risk factors are properly controlled. He critiques the patient’s prior diabetes and cholesterol management, noting the need for GLP-1 agonists, appropriate statin dosing, and target LDL <55 mg/dL. The group discusses poor provider adherence to guidelines and how metabolic disorders must be aggressively treated. |
| 20:32–27:08 | Lipid Therapy, Statins, PCSK9, and Perioperative Risk - They discuss rosuvastatin 20 mg (referencing the JUPITER Trial), ezetimibe, and PCSK9 inhibitors as ideal strategies for high-risk lipid control. The host explains perioperative statin benefits and stresses improving blood pressure management. TRT timing around CABG and perioperative clot risk are key topics. |
| 27:08–34:19 | Debating Continuation or Stopping Testosterone Before CABG - The clinicians evaluate whether TRT should continue before surgery. They note the TRAVERSE Trial’s support for testosterone’s cardiovascular safety but weigh this against the temporary increase in VTE risk during early TRT. They consider pausing therapy around surgery with plans to resume earlier than the typical six-month waiting period. |
| 34:19–42:02 | Case 2 Introduction (23-year-old male with severe symptoms) - Stephanie presents a young man on medical leave with profound fatigue, low mood, ED, muscle loss, and repeatedly low testosterone levels. His ferritin levels are extremely high, and his LH/FSH are suppressed, suggesting secondary hypogonadism likely tied to iron overload. |
| 42:02–1:00:50 | Hemochromatosis Diagnosis, Management & Treatment Strategy - The group identifies hereditary hemochromatosis as the likely cause of his pituitary suppression and hormonal collapse. They recommend genetic testing, hepatology referral, liver MRI, and urgent therapeutic phlebotomy. TRT is considered appropriate due to severe symptoms, provided iron overload is treated concurrently, and phlebotomy will need to continue for life. |
Meeting Summary
The session opens with the host introducing a clinical meeting where Stephanie presents two complex hormone-related cases. Before diving into the cases, the host discusses new advancements in cardiac imaging, particularly AI-driven CT angiography analysis, and emphasizes the importance of heart and kidney monitoring in testosterone therapy practices. He highlights that many clinics fail to take a comprehensive internal-medicine–based approach, stressing that androgen therapy requires proactive management of cardiovascular risk.
Stephanie’s first case involves a 61-year-old Canadian man with multiple comorbidities—type 2 diabetes, obesity, hypertension, sleep apnea, dyslipidemia, erectile dysfunction, and suspected peripheral arterial disease. Her assessment and labs led her to increase cardiometabolic medications, initiate testosterone, and refer him to cardiology. The cardiologist discovered multivessel coronary artery disease requiring urgent CABG. The group discusses why this should have been identified years earlier, emphasizing evidence-based management with GLP-1 agonists, SGLT2 inhibitors, proper statin intensification, and aggressive LDL lowering. They also debate postoperative testosterone management, referencing the Traverse trial to argue that TRT can be safe in men with existing heart disease when risk factors are well-controlled.
The second case centers on a 23-year-old man with profound fatigue, mood decline, sexual dysfunction, and extremely low testosterone levels. His labs reveal markedly elevated ferritin and low LH/FSH, pointing to secondary hypogonadism caused by hereditary hemochromatosis. The group praises Stephanie for identifying what multiple specialists had missed, noting the need for genetic testing, urgent hepatology referral, MRI evaluation for iron deposition, and therapeutic phlebotomy. They agree TRT is ethically appropriate given the patient’s severe symptoms, provided that iron overload is treated concurrently. The discussion highlights how iron toxicity can suppress pituitary function, how iron deposition can be reversible with treatment, and how long-term management requires lifelong monitoring and phlebotomy.
Drug Callouts with Descriptions
| Drug Name | Description |
|---|---|
| Testosterone (TRT / Testosterone Cypionate / Gel) | According to the Endocrine Society, testosterone replacement therapy is used to treat men with clinically confirmed hypogonadism to restore physiological testosterone levels and improve symptoms. In the video, TRT is discussed extensively for both patients—one with heart disease risk and one with severe hormone deficiency. The group debates timing of TRT around CABG surgery and also emphasizes TRT necessity in the young patient with profound secondary hypogonadism. |
| SGLT2 inhibitors (e.g., Empagliflozin, Dapagliflozin) | The American Diabetes Association states that SGLT2 inhibitors reduce blood glucose by promoting urinary glucose excretion and provide significant cardiovascular and renal protection. Stephanie increased the patient's SGLT2 inhibitor dose because he was undertreated and at very high cardiovascular risk. The host strongly supported this decision, emphasizing that SGLT2 inhibitors should be foundational therapy in diabetics—especially those undergoing cardiac evaluation. |
| GLP-1 receptor agonists (e.g., Semaglutide, Tirzepatide) | The ADA and AHA note that GLP-1 receptor agonists lower glucose, promote weight loss, and reduce major cardiovascular events in high-risk patients. The host repeatedly insists that the first patient urgently needs a GLP-1 agonist due to obesity, diabetes, and heart disease. It is presented as one of the biggest missed opportunities by his prior providers. |
| Aspirin | The American Heart Association describes aspirin as an antiplatelet drug that helps prevent blood clots and reduces risk of heart attack or stroke in appropriate patients. Stephanie initiated aspirin therapy in the 61-year-old patient due to severe erectile dysfunction (a vascular warning sign) and suspected peripheral arterial disease. Her decision was validated as appropriate given the patient’s later-confirmed multivessel coronary artery disease. |
| Statins (Rosuvastatin / Crestor) | The AHA explains that statins lower LDL cholesterol by inhibiting hepatic cholesterol synthesis and are first-line therapy for preventing cardiovascular events. The host criticizes the cardiologist for prescribing only 10 mg of rosuvastatin instead of evidence-based high-intensity doses. He cites the Jupiter Trial to argue for rosuvastatin 20 mg and stresses aggressively targeting LDL <55 mg/dL. |
| Ezetimibe (Zetia) | According to ACC guidelines, ezetimibe reduces cholesterol absorption in the intestine and is recommended when statins alone don’t achieve adequate LDL lowering. In the video, it is discussed as an important add-on for patients who cannot reach LDL goals. The host suggests combining it with a statin if PCSK9 inhibitors are not accessible. |
| PCSK9 inhibitors (evolocumab, alirocumab) | The AHA states that PCSK9 inhibitors dramatically lower LDL cholesterol and significantly reduce cardiovascular event risk in high-risk patients. The host promotes PCSK9 inhibitors as the first choice for aggressively lowering LDL in the severely diseased patient. He acknowledges cost barriers but stresses they are the gold-standard for life-saving LDL reduction. |
| Beta-blockers (Bisoprolol / Nebivolol) | The American College of Cardiology defines beta-blockers as medications that lower heart rate and blood pressure, reducing myocardial oxygen demand. Stephanie notes that the cardiologist prescribed bisoprolol post-diagnosis. The host discusses other options like nebivolol, praising its nitric oxide–mediated vasodilation. |
| Metformin | The ADA describes metformin as the first-line therapy for type 2 diabetes, improving insulin sensitivity and reducing hepatic glucose production. The host criticizes the patient's reliance on metformin alone given his severe cardiometabolic risk. He argues the patient needed modern cardioprotective agents rather than older therapies. |
| Sulfonylureas (e.g., Glyburide / Glipizide) | According to the ADA, sulfonylureas stimulate insulin secretion but carry risks including hypoglycemia and weight gain. The host states they are outdated and should “be banned” in modern diabetic management. He notes that the patient had been kept on old-fashioned therapy instead of guideline-recommended medications. |
| hCG (Human Chorionic Gonadotropin) | The Endocrine Society explains that hCG can stimulate testicular testosterone and sperm production by acting like LH. In the second case, Stephanie considers using hCG monotherapy or combining hCG with TRT. The patient preferred TRT plus hCG to preserve fertility while treating symptoms. |
Testosterone (TRT / Testosterone Cypionate / Gel)
According to the Endocrine Society, testosterone replacement therapy is used to treat men with clinically confirmed hypogonadism to restore physiological testosterone levels and improve symptoms. In the video, TRT is discussed extensively for both patients—one with heart disease risk and one with severe hormone deficiency. The group debates timing of TRT around CABG surgery and also emphasizes TRT necessity in the young patient with profound secondary hypogonadism.
SGLT2 inhibitors (e.g., Empagliflozin, Dapagliflozin)
The American Diabetes Association states that SGLT2 inhibitors reduce blood glucose by promoting urinary glucose excretion and provide significant cardiovascular and renal protection. Stephanie increased the patient's SGLT2 inhibitor dose because he was undertreated and at very high cardiovascular risk. The host strongly supported this decision, emphasizing that SGLT2 inhibitors should be foundational therapy in diabetics—especially those undergoing cardiac evaluation.
GLP-1 receptor agonists (e.g., Semaglutide, Tirzepatide)
The ADA and AHA note that GLP-1 receptor agonists lower glucose, promote weight loss, and reduce major cardiovascular events in high-risk patients. The host repeatedly insists that the first patient urgently needs a GLP-1 agonist due to obesity, diabetes, and heart disease. It is presented as one of the biggest missed opportunities by his prior providers.
Aspirin
The American Heart Association describes aspirin as an antiplatelet drug that helps prevent blood clots and reduces risk of heart attack or stroke in appropriate patients. Stephanie initiated aspirin therapy in the 61-year-old patient due to severe erectile dysfunction (a vascular warning sign) and suspected peripheral arterial disease. Her decision was validated as appropriate given the patient’s later-confirmed multivessel coronary artery disease.
Statins (Rosuvastatin / Crestor)
The AHA explains that statins lower LDL cholesterol by inhibiting hepatic cholesterol synthesis and are first-line therapy for preventing cardiovascular events. The host criticizes the cardiologist for prescribing only 10 mg of rosuvastatin instead of evidence-based high-intensity doses. He cites the Jupiter Trial to argue for rosuvastatin 20 mg and stresses aggressively targeting LDL <55 mg/dL.
Ezetimibe (Zetia)
According to ACC guidelines, ezetimibe reduces cholesterol absorption in the intestine and is recommended when statins alone don’t achieve adequate LDL lowering. In the video, it is discussed as an important add-on for patients who cannot reach LDL goals. The host suggests combining it with a statin if PCSK9 inhibitors are not accessible.
PCSK9 inhibitors (evolocumab, alirocumab)
The AHA states that PCSK9 inhibitors dramatically lower LDL cholesterol and significantly reduce cardiovascular event risk in high-risk patients. The host promotes PCSK9 inhibitors as the first choice for aggressively lowering LDL in the severely diseased patient. He acknowledges cost barriers but stresses they are the gold-standard for life-saving LDL reduction.
Beta-blockers (Bisoprolol / Nebivolol)
The American College of Cardiology defines beta-blockers as medications that lower heart rate and blood pressure, reducing myocardial oxygen demand. Stephanie notes that the cardiologist prescribed bisoprolol post-diagnosis. The host discusses other options like nebivolol, praising its nitric oxide–mediated vasodilation.
Metformin
The ADA describes metformin as the first-line therapy for type 2 diabetes, improving insulin sensitivity and reducing hepatic glucose production. The host criticizes the patient's reliance on metformin alone given his severe cardiometabolic risk. He argues the patient needed modern cardioprotective agents rather than older therapies.
Sulfonylureas (e.g., Glyburide / Glipizide)
According to the ADA, sulfonylureas stimulate insulin secretion but carry risks including hypoglycemia and weight gain. The host states they are outdated and should “be banned” in modern diabetic management. He notes that the patient had been kept on old-fashioned therapy instead of guideline-recommended medications.
hCG (Human Chorionic Gonadotropin)
The Endocrine Society explains that hCG can stimulate testicular testosterone and sperm production by acting like LH. In the second case, Stephanie considers using hCG monotherapy or combining hCG with TRT. The patient preferred TRT plus hCG to preserve fertility while treating symptoms.
Condition Callouts with Descriptions
| Condition Name | Description |
|---|---|
| Coronary Artery Disease (CAD) | The AHA defines CAD as plaque buildup in the coronary arteries, reducing blood flow to the heart and increasing risk of heart attack. The first patient is found to have severe multivessel CAD requiring CABG. The host stresses this should have been detected years earlier based on risk factors and ED symptoms. |
| Acute Coronary Syndrome (ACS) | According to the AHA, ACS refers to any condition caused by sudden reduced blood flow to the heart, such as unstable angina or myocardial infarction. The host believes the patient was essentially experiencing ACS due to the severity of his blockages. It underscores the urgency of Stephanie’s referral. |
| Type 2 Diabetes | The ADA states that type 2 diabetes is a chronic disorder of insulin resistance and impaired insulin secretion leading to elevated blood glucose. The patient’s diabetes was poorly controlled, contributing to severe vascular disease. The host discusses how aggressive modern treatment could have prevented long-term damage. |
| Erectile Dysfunction (ED) | The NIH defines ED as the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance. In the video, ED is described as an early warning sign of cardiovascular disease. Stephanie’s recognition of ED as a vascular marker helped uncover the patient’s life-threatening heart disease. |
| Peripheral Arterial Disease (PAD) | The AHA defines PAD as narrowing of peripheral arteries, typically in the legs, due to atherosclerosis. The patient had suspected PAD from podiatrist findings, further supporting vascular pathology. This was part of the rationale for urgent cardiology referral. |
| Hypertension | The CDC states hypertension is chronically elevated blood pressure that increases risk of stroke, heart failure, and kidney disease. The patient’s blood pressure was borderline managed but not optimized. The host suggests better antihypertensive choices, including beta-blockers like nebivolol. |
| Dyslipidemia / High LDL | The AHA describes dyslipidemia as abnormal lipid levels, especially elevated LDL cholesterol. The host stresses the patient’s LDL goal should be <55 mg/dL given his high-risk profile. He critiques inadequate statin use and highlights evidence-based lipid-lowering strategies. |
| Obesity | The CDC defines obesity as excessive fat accumulation that increases risk of metabolic and cardiovascular disease. The first patient had class II obesity, worsening his diabetes, ED, and cardiac risks. The group strongly advocates GLP-1 agonists for weight and cardiovascular improvement. |
| Sleep Apnea | The American Academy of Sleep Medicine describes obstructive sleep apnea as repeated airway obstruction during sleep, causing oxygen drops and sleep disruption. The patient had known sleep apnea and used CPAP, but still suffered fatigue. The host notes sleep apnea contributes to vascular disease and erythrocytosis risk. |
| Secondary Hypogonadism | The Endocrine Society defines secondary hypogonadism as low testosterone caused by inadequate pituitary stimulation (low LH/FSH). The 23-year-old had profoundly low LH/FSH and extremely low testosterone. This was ultimately linked to iron overload damaging the pituitary. |
| Hereditary Hemochromatosis | The NIH describes hereditary hemochromatosis as a genetic disorder causing excessive intestinal iron absorption and organ iron deposition. In the second case, ferritin >1000 and family history pointed strongly to this condition. The group explains how iron infiltrates the pituitary, causing secondary hypogonadism. |
| Liver Iron Overload | The NIH notes that iron overload causes liver fibrosis, cirrhosis, and long-term organ damage. The hosts share past cases where MRI confirmed liver iron deposition, and phlebotomy prevented progression. The second patient likely already has early organ involvement. |
| Venous Thromboembolism (VTE) / DVT / PE | The American Society of Hematology defines VTE as blood clots in the deep veins or lungs, often triggered by immobility or pro-thrombotic states. The panel discusses the temporary increased VTE risk in the first 6–12 months of TRT. This is central to their debate on timing TRT before or after CABG. |
| CABG (Coronary Artery Bypass Grafting) | The AHA describes CABG as a surgical procedure using grafts to bypass blocked coronary arteries. The first patient must undergo CABG due to severe multivessel disease. The group covers perioperative medication considerations, including statins, anticoagulation, and possible temporary TRT pause. |
Coronary Artery Disease (CAD)
The AHA defines CAD as plaque buildup in the coronary arteries, reducing blood flow to the heart and increasing risk of heart attack. The first patient is found to have severe multivessel CAD requiring CABG. The host stresses this should have been detected years earlier based on risk factors and ED symptoms.
Acute Coronary Syndrome (ACS)
According to the AHA, ACS refers to any condition caused by sudden reduced blood flow to the heart, such as unstable angina or myocardial infarction. The host believes the patient was essentially experiencing ACS due to the severity of his blockages. It underscores the urgency of Stephanie’s referral.
Type 2 Diabetes
The ADA states that type 2 diabetes is a chronic disorder of insulin resistance and impaired insulin secretion leading to elevated blood glucose. The patient’s diabetes was poorly controlled, contributing to severe vascular disease. The host discusses how aggressive modern treatment could have prevented long-term damage.
Erectile Dysfunction (ED)
The NIH defines ED as the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance. In the video, ED is described as an early warning sign of cardiovascular disease. Stephanie’s recognition of ED as a vascular marker helped uncover the patient’s life-threatening heart disease.
Peripheral Arterial Disease (PAD)
The AHA defines PAD as narrowing of peripheral arteries, typically in the legs, due to atherosclerosis. The patient had suspected PAD from podiatrist findings, further supporting vascular pathology. This was part of the rationale for urgent cardiology referral.
Hypertension
The CDC states hypertension is chronically elevated blood pressure that increases risk of stroke, heart failure, and kidney disease. The patient’s blood pressure was borderline managed but not optimized. The host suggests better antihypertensive choices, including beta-blockers like nebivolol.
Dyslipidemia / High LDL
The AHA describes dyslipidemia as abnormal lipid levels, especially elevated LDL cholesterol. The host stresses the patient’s LDL goal should be <55 mg/dL given his high-risk profile. He critiques inadequate statin use and highlights evidence-based lipid-lowering strategies.
Obesity
The CDC defines obesity as excessive fat accumulation that increases risk of metabolic and cardiovascular disease. The first patient had class II obesity, worsening his diabetes, ED, and cardiac risks. The group strongly advocates GLP-1 agonists for weight and cardiovascular improvement.
Sleep Apnea
The American Academy of Sleep Medicine describes obstructive sleep apnea as repeated airway obstruction during sleep, causing oxygen drops and sleep disruption. The patient had known sleep apnea and used CPAP, but still suffered fatigue. The host notes sleep apnea contributes to vascular disease and erythrocytosis risk.
Secondary Hypogonadism
The Endocrine Society defines secondary hypogonadism as low testosterone caused by inadequate pituitary stimulation (low LH/FSH). The 23-year-old had profoundly low LH/FSH and extremely low testosterone. This was ultimately linked to iron overload damaging the pituitary.
Hereditary Hemochromatosis
The NIH describes hereditary hemochromatosis as a genetic disorder causing excessive intestinal iron absorption and organ iron deposition. In the second case, ferritin >1000 and family history pointed strongly to this condition. The group explains how iron infiltrates the pituitary, causing secondary hypogonadism.
Liver Iron Overload
The NIH notes that iron overload causes liver fibrosis, cirrhosis, and long-term organ damage. The hosts share past cases where MRI confirmed liver iron deposition, and phlebotomy prevented progression. The second patient likely already has early organ involvement.
Venous Thromboembolism (VTE) / DVT / PE
The American Society of Hematology defines VTE as blood clots in the deep veins or lungs, often triggered by immobility or pro-thrombotic states. The panel discusses the temporary increased VTE risk in the first 6–12 months of TRT. This is central to their debate on timing TRT before or after CABG.
CABG (Coronary Artery Bypass Grafting)
The AHA describes CABG as a surgical procedure using grafts to bypass blocked coronary arteries. The first patient must undergo CABG due to severe multivessel disease. The group covers perioperative medication considerations, including statins, anticoagulation, and possible temporary TRT pause.
Meeting Key Takeaways
◉ Cardiovascular screening is essential in hormone therapy. The host stresses that testosterone clinics should treat patients like internal-medicine patients—monitoring heart, kidney, cholesterol, and diabetes risks instead of focusing only on hormones.
◉ Traditional calcium scoring is becoming outdated. AI-driven CT angiography platforms (such as Cleerly) offer more precise plaque characterization and are becoming the preferred method for evaluating heart disease risk.
◉ The first patient’s life-threatening heart disease was missed for years. A 61-year-old man with obesity, diabetes, erectile dysfunction, and poor metabolic control was not properly screened by prior providers, yet Stephanie identified the problem and cardiology found severe multivessel disease requiring CABG.
◉ Evidence supports the safe use of testosterone in men with heart disease when risks are controlled. The group discusses the Traverse Trial, which showed no increased risk of heart attack or stroke in men with existing cardiovascular disease who were treated with testosterone—provided that blood pressure, cholesterol, and diabetes are aggressively managed.
◉ GLP-1 agonists, SGLT2 inhibitors, and appropriate statin therapy are crucial in high-risk patients. The experts emphasize that proper cardiometabolic medication—not underdosed statins or old diabetes drugs—is critical in reducing heart disease risk and improving surgical outcomes.
◉ The second patient likely has hereditary hemochromatosis causing secondary hypogonadism. The 23-year-old with very low testosterone and extremely high ferritin appears to have iron overload affecting pituitary function—a condition several previous specialists failed to diagnose.
◉ Management of iron overload requires phlebotomy, specialist referral, and continuation of testosterone when clinically necessary. The experts explain that with hemochromatosis, patients need ongoing phlebotomy to lower ferritin, specialist evaluation (hematology, hepatology), and in severe symptomatic cases, testosterone therapy can ethically be continued alongside iron management.
More Testosteronologist™ Meetings
Previous